Home » Stocks » IMRA

IMARA Inc. (IMRA)

Stock Price: $5.48 USD 0.10 (1.86%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $5.50 +0.02 (0.37%) Jul 26, 6:33 PM
Market Cap 140.85M
Revenue (ttm) n/a
Net Income (ttm) -44.40M
Shares Out 17.85M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $5.48
Previous Close $5.38
Change ($) 0.10
Change (%) 1.86%
Day's Open 5.57
Day's Range 5.38 - 5.71
Day's Volume 220,154
52-Week Range 5.20 - 36.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Imara Inc (NASDAQ: IMRA) has priced its previously announced underwritten public offering of shares at $6.00 per share for gross proceeds of $50 million. The offering will close by July 16.

1 week ago - Benzinga

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...

1 week ago - GlobeNewsWire

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...

1 week ago - GlobeNewsWire

Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as ...

Other stocks mentioned: ATHA, CCXI, IMVT, SGTX
3 weeks ago - Benzinga

Imara has continued and expanded the program to award 30 grants totaling $150,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Im...

1 month ago - GlobeNewsWire

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687

1 month ago - GlobeNewsWire

Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor performa...

Other stocks mentioned: TARA
1 month ago - GuruFocus

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial

1 month ago - GlobeNewsWire

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021

2 months ago - GlobeNewsWire

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering ...

2 months ago - GlobeNewsWire

Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families Company will award grants totalin...

3 months ago - GlobeNewsWire

Atlanta, Georgia--(Newsfile Corp. - March 22, 2021) - Holzer & Holzer, LLC is investigating whether IMARA Inc. ("IMARA" or the "Company") (NASDAQ: IMRA) complied with federal securities laws. On March 5...

4 months ago - Newsfile Corp

Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised ...

4 months ago - Newsfile Corp

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA).   Such investors are advised to contact R...

4 months ago - PRNewsWire

NEW YORK, March 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA).  Such investors are advised to contact Rob...

4 months ago - PRNewsWire

Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia

4 months ago - GlobeNewsWire

BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

4 months ago - GlobeNewsWire

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

5 months ago - GlobeNewsWire

Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical...

6 months ago - GlobeNewsWire

Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap f...

6 months ago - Benzinga

Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment

7 months ago - GlobeNewsWire

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

7 months ago - GlobeNewsWire

Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experience in the p...

8 months ago - GlobeNewsWire

IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Patient Dosing Underway in Phase 2b clinical trials of IMR-687  in sickle cell disease and beta-thalassemia

8 months ago - GlobeNewsWire

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

8 months ago - GlobeNewsWire

Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease Forte is the first clinical ...

9 months ago - GlobeNewsWire

Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare Conference Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare C...

10 months ago - GlobeNewsWire

BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

11 months ago - GlobeNewsWire

IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial

11 months ago - GlobeNewsWire

Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease Highly selective, potent, small molecule inhibitor...

11 months ago - GlobeNewsWire

BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

11 months ago - GlobeNewsWire

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

11 months ago - GlobeNewsWire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: COWN, GAN, GTY
1 year ago - Zacks Investment Research

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi...

1 year ago - GlobeNewsWire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, KROS, PCVX, RNA, RPTX, XBI ...
1 year ago - CNN Business

Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Company expands program...

1 year ago - GlobeNewsWire

BOSTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients ...

1 year ago - GlobeNewsWire

Imara Inc. IMRA, +12.66% announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment.

1 year ago - Market Watch

Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of monothe...

1 year ago - GlobeNewsWire

About IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
IPO Date
Mar 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
IMRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IMARA Inc. stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 538.69% from the latest price.

Price Target
$35.00
(538.69% upside)
Analyst Consensus: Strong Buy